Vitekta Interactions
There are 103 drugs known to interact with Vitekta (elvitegravir), along with 2 disease interactions, and 2 alcohol/food interactions. Of the total drug interactions, 20 are major, and 83 are moderate.
- View all 103 medications that may interact with Vitekta
- View Vitekta alcohol/food interactions (2)
- View Vitekta disease interactions (2)
Most frequently checked interactions
View interaction reports for Vitekta (elvitegravir) and the medicines listed below.
- Aptivus (tipranavir)
- Avastin (bevacizumab)
- Blincyto (blinatumomab)
- Cerdelga (eliglustat)
- Corlanor (ivabradine)
- Crixivan (indinavir)
- Enbrel (etanercept)
- Entyvio (vedolizumab)
- Fasenra (benralizumab)
- Hemlibra (emicizumab)
- Intelence (etravirine)
- Isentress (raltegravir)
- Kalydeco (ivacaftor)
- Matulane (procarbazine)
- Norvir (ritonavir)
- NovoSeven RT (coagulation factor viia)
- Ofev (nintedanib)
- Orfadin (nitisinone)
- Prolia (denosumab)
- Pulmozyme (dornase alfa)
- Ravicti (glycerol phenylbutyrate)
- Regroton (chlorthalidone / reserpine)
- Remicade (infliximab)
- Repatha (evolocumab)
- Rescriptor (delavirdine)
- Revlimid (lenalidomide)
- Simulect (basiliximab)
- Stivarga (regorafenib)
- Sucraid (sacrosidase)
- Tecentriq (atezolizumab)
Vitekta alcohol/food interactions
There are 2 alcohol/food interactions with Vitekta (elvitegravir).
Vitekta disease interactions
There are 2 disease interactions with Vitekta (elvitegravir) which include:
Report options
QR code containing a link to this page
More about Vitekta (elvitegravir)
- Vitekta consumer information
- Compare alternatives
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: integrase strand transfer inhibitor
- Breastfeeding
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.